Meropenem 1000 mg + Sulbactam 500 mg Injection – MORPEX SB 1500

Meropenem 1000 mg + Sulbactam 500 mg Injection – Broad-Spectrum Power, against multidrug-resistant bacteria.

MORPEX SB 1500 Injection – Meropenem 1000 mg + Sulbactam 500 mg Injection is a combination of Meropenem, a broad-spectrum carbapenem antibiotic, and sulbactam, a beta-lactamase inhibitor, designed to combat severe bacterial infections. It works by inhibiting bacterial cell wall synthesis; it exerts a potent bactericidal effect, leading to bacterial cell death. It remains highly stable against β-lactamase-producing bacteria, including extended-spectrum β-lactamases (ESBL), making it a reliable choice for treating resistant infections. Sulbactam prevents bacterial enzymes from breaking down Meropenem, thereby enhancing its efficacy against resistant pathogens, including extended-spectrum β-lactamase (ESBL)-producing bacteria.

Recommended by Specialists:
✅Pulmonologists – To treat severe pneumonia, ventilator-associated pneumonia, and lower respiratory tract infections.
✅Nephrologists – For complicated urinary tract infections (UTIs) and pyelonephritis caused by resistant pathogens.
✅General Surgeons – For treating complicated intra-abdominal infections and post-surgical infections.

Key Benefits of Meropenem 1000 mg + Sulbactam 500 mg Injection – MORPEX SB 1500:
✅Enhanced Broad-Spectrum Action – Combines Meropenem, a powerful carbapenem antibiotic, with Sulbactam, a β-lactamase inhibitor, to effectively combat drug-resistant infections.
✅Superior β-Lactamase Resistance – Sulbactam enhances Meropenem’s activity by neutralizing β-lactamase enzymes, making it effective against multidrug-resistant bacteria.
✅Rapid & Potent Bactericidal Effect – Disrupts bacterial cell wall synthesis, ensuring fast and effective bacterial eradication.
✅Effective against Multidrug-Resistant Organisms – Ideal for treating severe hospital-acquired infections caused by ESBL-producing and carbapenem-resistant bacteria.
✅Reliable for Critical Infections – Used in ICUs and critical care settings for life-threatening infections such as sepsis, pneumonia, and complicated urinary tract infections.
✅Reduced Risk of Resistance Development – Dual-action formulation helps minimize the emergence of antibiotic resistance, ensuring sustained efficacy.

Indications:
✅Severe respiratory tract infections (including ventilator-associated pneumonia)
✅Complicated urinary tract infections (UTIs) and pyelonephritis
✅Complicated intra-abdominal infections
✅Skin and soft tissue infections
✅Sepsis and septic shock
✅Bacterial meningitis
✅Multidrug-resistant infections